Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy-Reference-Cited by-同舟云学术

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

Published:2021-05 Issue: Volume:149 Page:153-164
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ghisoni E.,Wicky A.,Bouchaab H.,Imbimbo M.,Delyon J.,Gautron Moura B.,Gérard C.L.,Latifyan S.,Özdemir B.C.,Caikovski M.,Pradervand S.,Tavazzi E.^ORCID,Gatta R.^ORCID,Marandino L.,Valabrega G.,Aglietta M.,Obeid M.,Homicsko K.,Mederos Alfonso N.N.^ORCID,Zimmermann S.,Coukos G.,Peters S.^ORCID,Cuendet M.A.,Di Maio M.,Michielin O.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat Rev Clin Oncol,2019

2. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis;Xing;J Immunother Canc,2019

3. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis;Duan;JAMA Oncol,2019

4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Haanen;Ann Oncol,2017

5. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors;Romanski;Eur J Canc,2020

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma;Immuno-Oncology and Technology;2024-12

2. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis;Annals of Oncology;2024-10

3. Delayed-Onset Immune-Related Colitis Following Pancreaticoduodenectomy in Patients With Gastric Cancer and Pancreatic Invasion Treated With Immune Checkpoint Inhibitors;Cureus;2024-09-02

4. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma;Nature Cancer;2024-08-29

5. First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?;Lung Cancer;2024-08